Edge Therapeutics, Inc. Contracts & Agreements

Amendment to the Eighth Amended and Restated Certificate of Incorporation (Filed With SEC on June 24, 2024)

Executive Employment Agreement by and between Stephan F. Toutain and PDS Biotechnology Corporation, effective as of May 1, 2024 (Filed With SEC on May 15, 2024)

Executive Employment Agreement by and between Lars Boesgaard and PDS Biotechnology Corporation, effective as of November 28, 2023 (Filed With SEC on March 28, 2024)

Executive Employment Agreement by and between Kirk V. Shephard, M.D. and PDS Biotechnology Corporation, effective as of January 22, 2024 (Filed With SEC on March 28, 2024)

PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on January 22, 2024)

Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (Filed With SEC on July 17, 2023)

License Agreement dated as of December 30, 2022 by and between Merck KGaA, Darmstadt, Germany and PDS Biotechnology Corporation (Filed With SEC on March 28, 2023)

Share Transfer Agreement by and between PDS Biotechnology Corporation and Merck KGaA, Darmstadt, Germany (Filed With SEC on January 3, 2023)

Form of Warrant issued under the Venture Loan and Security Agreement, dated August 24, 2022 (Filed With SEC on November 14, 2022)

Venture Loan and Security Agreement, dated August 24, 2022, by and among Horizon Technology Finance Corporation, as a lender and collateral agent, Powerscourt Investments XXV, LP,... (Filed With SEC on November 14, 2022)

Executive Employment Agreement by and between Spencer Brown and PDS Biotechnology Corporation, effective as of June 1, 2022 (Filed With SEC on August 8, 2022)

Amended and Restated Preclinical/Clinical Collaboration and License Agreement dated as of November 30, 2020 by and between PDS Biotechnology Corporation and Farmacore Biotechnology (Filed With SEC on August 8, 2022)

First Amendment to Preclinical/Clinical Collaboration and License Agreement dated as of November 22, 2021 by and between PDS Biotechnology Corporation and Farmacore Biotechnology (Filed With SEC on August 8, 2022)

PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on May 18, 2022)

Patent License Agreement dated as of November 5, 2021, by and between PDS Biotechnology Corporation and the U.S. Department of Health and Human Services, as represented by the... (Filed With SEC on March 31, 2022)

Option Agreement with University of Georgia Research Foundation, Inc. effective as of October 25, 2021 (Filed With SEC on March 31, 2022)

PDS Biotechnology Corporation Change of Control Severance Plan effective as of March 14, 2022 (Filed With SEC on March 31, 2022)

Amended and Restated Executive Employment Agreement by and between Frank K. Bedu-Addo and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)

Executive Employment Agreement by and between Gregory Conn, Ph.D. and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)

Executive Employment Agreement by and between Matthew Hill and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)

Executive Employment Agreement by and between Lauren V. Wood, M.D. and PDS Biotechnology Corporation, effective as of March 14, 2022 (Filed With SEC on March 31, 2022)

Executive Employment Agreement by and between PDS Biotechnology Corporation and Matthew Hill, dated as of October 4, 2021 (Filed With SEC on October 6, 2021)

Amendment to Employment Agreement by and between PDS Biotechnology Corporation and Gregory Conn, Ph.D., effective as of June 17, 2021 (Filed With SEC on June 21, 2021)

Underwriting Agreement, dated June 15, 2021, by and among PDS Biotechnology Corporation and Cantor Fitzgerald & Co (Filed With SEC on June 17, 2021)

Executive Employment Agreement by and between the Company and Seth L. Van Voorhees, Ph.D (Filed With SEC on December 9, 2020)

PDS Biotechnology Corporation 2019 Inducement Plan, as amended (Filed With SEC on December 9, 2020)

Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (Filed With SEC on December 9, 2020)

Form of Employee Stock Option Agreement under the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (Filed With SEC on December 9, 2020)

Underwriting Agreement dated August 11, 2020 (Filed With SEC on August 13, 2020)

Consulting Agreement (Michael King) (Filed With SEC on June 24, 2020)

Description of Securities (Filed With SEC on March 27, 2020)

Sublease Agreement, effective as of March 5, 2020, by and between PDS Biotechnology Corporation and COWI North America, Inc (Filed With SEC on March 27, 2020)

Form of Underwriting Agreement (Filed With SEC on January 17, 2020)

Amendment No. 1 to Clinical Trial Collaboration and Supply Agreement, dated as of October 28, 2019, by and between PDS Biotechnology Corporation and MSD International GmbH (Filed With SEC on November 7, 2019)

Employment Agreement, effective June 1, 2019, by and between PDS Biotechnology Corporation and Gregory Conn (Filed With SEC on August 1, 2019)

Offer Letter, dated February 1, 2019, by and between PDS Biotechnology Corporation and Lauren V. Wood, M.D (Filed With SEC on August 1, 2019)

Registration Rights Agreement, dated July 29, 2019, between PDS Biotechnology Corporation and Aspire Capital Fund, LLC (Filed With SEC on July 30, 2019)

Common Stock Purchase Agreement, dated July 29, 2019 between PDS Biotechnology Corporation and Aspire Capital Fund, LLC (Filed With SEC on July 30, 2019)

PDS Biotechnology Corporation 2019 Inducement Plan (Filed With SEC on June 20, 2019)

Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Inducement Plan (Filed With SEC on June 20, 2019)

Letter Agreement, dated as of February 3, 2019, by and among Edge Therapeutics, Inc., PDS Biotechnology Corporation and Brian A. Leuthner (Filed With SEC on February 4, 2019)

Amendment No. 1 to Agreement and Plan of Merger and Reorganization, dated as of January 24, 2019, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc. and PDS... (Filed With SEC on January 30, 2019)

Employment Agreement, dated October 11, 2018, by and between PDS Biotechnology Corporation and Frank K. Bedu-Addo (Filed With SEC on December 21, 2018)

Consulting Services Agreement, dated December 15, 2014, by and between PDS Biotechnology Corporation and Gregory Freitag (Filed With SEC on December 21, 2018)

Consulting Services Agreement, dated December 15, 2014, by and between PDS Biotechnology Corporation and DeLyle Bloomquist (Filed With SEC on December 21, 2018)

Offer Letter, dated September 21, 2018, by and between PDS Biotechnology Corporation and Lauren Wood, MD (Filed With SEC on December 21, 2018)

Consulting Services Agreement, dated March 26, 2015, by and between PDS Biotechnology Corporation and Gregory Conn (Filed With SEC on December 21, 2018)

Agreement and Plan of Merger and Reorganization, dated November 23, 2018, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc. and PDS Biotechnology Corporation (Filed With SEC on November 26, 2018)

Form of Support Agreement, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc., PDS Biotechnology Corporation and certain of PDS Biotechnology Corporations directors,... (Filed With SEC on November 26, 2018)

Form of Support Agreement, by and among Edge Therapeutics, Inc., Echos Merger Sub, Inc., PDS Biotechnology Corporation and certain of Edge Therapeutics, Inc.s directors, officers... (Filed With SEC on November 26, 2018)

Executive Employment Agreement by and between Andrew Saik and Edge entered into as of October 31, 2017 (Filed With SEC on November 1, 2017)

Amended and Restated Master Formulation Development Agreement by and between the Company and Oakwood Laboratories LLC, dated as of June 30, 2017 (Filed With SEC on August 1, 2017)

Manufacturing and Supply Agreement by and between the Company and Oakwood Laboratories LLC, dated as of June 30, 2017 (Filed With SEC on August 1, 2017)

Form of Subscription Agreement dated April 19, 2017, between Edge Therapeutics, Inc. and certain investors (Filed With SEC on April 19, 2017)

Separation and General Release Agreement, by and between Edge Therapeutics, Inc. and Andrew J. Einhorn, dated March 13, 2017 (Filed With SEC on March 15, 2017)

Employment Agreement by and between Alyssa Wyant and the Company, dated as of February 21, 2017 (Filed With SEC on March 2, 2017)

Form of Executive Stock Option Agreement (Filed With SEC on March 2, 2017)

Form of Employee Stock Option Agreement (Filed With SEC on March 2, 2017)

Amended and Restated Loan and Security Agreement, dated as of August 1, 2016, by and between the Company and Hercules Capital, Inc (Filed With SEC on November 1, 2016)

Executive Employment Agreement by and between Daniel Brennan and Edge Therapeutics, Inc. entered into as of October 17, 2016 (Filed With SEC on October 18, 2016)

Lease, dated February 18, 2016, between The Connell Company and Edge Therapeutics, Inc (Filed With SEC on May 3, 2016)

Master Formulation Development Agreement by and between the Company and Oakwood Laboratories LLC, dated as of March 12, 2015 (Filed With SEC on March 8, 2016)

Warrant to Purchase 18,000 Shares of Common Stock issued to Maxim Partners LLC, dated as of October 6, 2015 (Filed With SEC on November 6, 2015)

EXECUTIVEEMPLOYMENT AGREEMENT (Filed With SEC on November 5, 2015)

EDGE THERAPEUTICS, INC. Common Stock, par value $0.00033 pershare UNDERWRITING AGREEMENT (Filed With SEC on September 21, 2015)

EDGE THERAPEUTICS, INC. 2010 EQUITY INCENTIVE PLAN (Filed With SEC on September 21, 2015)

EDGE THERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN (Filed With SEC on September 21, 2015)

EDGE THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN Adopted by the Board of DirectorsAugust 27, 2014 Approved by the Shareholders November 3, 2014 (Filed With SEC on September 21, 2015)

SECONDAMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on September 21, 2015)

CONFIDENTIAL MATERIAL OMITTED AND FILEDSEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS. AMENDMENT NO. 1 TO THE LICENSE AGREEMENT (Filed With SEC on September 21, 2015)

EDGE THERAPEUTICS, INC. WARRANT TO PURCHASE 16,667 SHARES OF CAPITAL STOCK (Filed With SEC on August 14, 2015)

FIRST AMENDMENT TO WARRANT NO. 1 (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS, INC. WARRANT TO PURCHASE [______] SHARES OF COMMON STOCK (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS, INC. Preferred Stock Warrant (Filed With SEC on August 14, 2015)

WARRANT AGREEMENT To Purchase Shares of Preferred Stock of EDGE THERAPEUTICS, INC. Dated as of August28, 2014 (the Effective Date) (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS, INC. Preferred Stock Warrant (Filed With SEC on August 14, 2015)

INVESTORSRIGHTS AGREEMENT byand among EdgeTherapeutics, Inc., VenrockHealthcare Capital Partners II, L.P., and theother Investors named herein April6, 2015 (Filed With SEC on August 14, 2015)

CONFIDENTIAL MATERIALOMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKSDENOTE SUCH OMISSIONS. LICENSE AGREEMENT (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS, INC. 2010 EQUITY INCENTIVE PLAN (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS, INC. 2012 EQUITY INCENTIVE PLAN (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN Adopted by the Board of DirectorsAugust 27, 2014 Approved by the Shareholders November 3, 2014 (Filed With SEC on August 14, 2015)

EDGE THERAPEUTICS,INC. SECOND AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2015)

AMENDEDAND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2015)

SECONDAMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2015)

INDEMNIFICATION AGREEMENT (Filed With SEC on August 14, 2015)

LOAN ANDSECURITY AGREEMENT (Filed With SEC on August 14, 2015)

AMENDMENT TO THEedge therapeutics, inc. 2010 EQUITYINCENTIVE Plan (Filed With SEC on August 14, 2015)

AMENDMENT NO. 1 TO LOAN AND SECURITY AGREEMENT (Filed With SEC on August 14, 2015)

AMENDEDAND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2015)

Category

Industry

Companies

Contracts

Edge Therapeutics, Inc. Contracts & Agreements